Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study
Morales D, Bu F, Viernes B, DuVall S, Matheny M, Simon K, Falconer T, Richter L, Ostropolets A, Lau W, Man K, Chattopadhyay S, Mathioudakis N, Minty E, Nishimura A, Sun F, Yin C, Seager S, Chai Y, Zhou J, Lu Y, Reyes C, Pistillo A, Duarte-Salles T, Blacketer C, Schuemie M, Ryan P, Krumholz H, Hripcsak G, Khera R, Suchard M. Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study. Diabetes Care 2025, 48: 1386-1394. PMID: 40465422, PMCID: PMC12281980, DOI: 10.2337/dc25-0154.Peer-Reviewed Original ResearchRisk of thyroid tumorThyroid tumorsGLP-1RADPP-4isHazard ratioThyroid malignancyCohort studyIncreased riskSodium-glucose cotransporter 2 inhibitorsElectronic health record databaseGlucagon-like peptide 1 receptor agonistsEstimate hazard ratiosRandom-effects meta-analysisGLP-1 receptor agonistsPeptide 1 receptor agonistsDipeptidyl peptidase 4 inhibitorsThyroid tumor incidenceUsers of SGLT2isHealth record databaseSecond-line treatmentType 2 diabetes mellitusNew-user cohort studyRetrospective cohort studyUsers of sulfonylureasIntention-to-treat
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply